Conclusions
Thromboembolic events were seen despite the anticoagulant prophylaxis in our study. Development of thrombosis were associated with hyperinflammation in patients with severe and critical COVID-19. Intravenous high-dose anakinra treatment decreases both venous and arterial events in patients with COVID-19.
Acknowledgments: Many thanks to Prof. Ahmet Gül for shedding ligh of our way.